Ceftolozane

Ceftolozane is a semi-synthetic broad-spectrum fifth generation cephalosporin. It was approved by the FDA in 2014 for use in combination with [Tazobactam] for the treatment of serious infections, including intra-abdominal infections and complicated urinary tract infections. The manufacturer of this drug is Cubist Pharmaceuticals. Most recently, in June 2019, ceftolozane-tazobactam was approved for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Hospital-acquired pneumonia and ventilator-associated pneumonia are major causes of morbidity and mortality in hospitalized patients and the use of ceftolozane-tazobactam offers effective activity against various organisms causing these infections, including Pseudomonas aeruginosa. It is grouped under the following drug class(es): Beta-lactams and Cephalosporins. Its therapeutic use is listed as anti-infectives and antibiotics. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include ceftolozano and ceftolozanum. Its PubChem CID is 53234134.